Phio Pharmaceuticals Corp. is a clinical stage biopharmaceutical company that develops therapies using its proprietary INTASYL® siRNA gene silencing technology. This technology aims to enhance the effectiveness of immune cells in targeting and killing cancer cells. Phio focuses on the treatment of cutaneous squamous cell carcinoma (cSCC) and melanoma, leveraging advancements in RNA interference (RNAi) for applications in immuno-oncology.
